Literature DB >> 23465508

Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia.

Manuel Delgado-Alvarado1, María José Sedano, Vicente González-Quintanilla, Enrique Marco de Lucas, José Miguel Polo, José Berciano.   

Abstract

Idiopathic CD4 lymphocytopenia (ICL) is a syndrome described in patients with low counts of CD4 cells and no other causes for immunosuppression. A few cases of progressive multifocal leukoencephalopathy (PML) have been described in association with this entity. There is no effective treatment for any of them, and the clinical course and outcome are unpredictable. We report on a case of ICL with PML and review the literature, trying to identify the clinical features and the prognosis clues associated to these entities together. A 72-year-old man presented with acute onset gait instability that progressed to a severe cerebellar syndrome with cognitive decline. A cranial MRI showed findings consistent with PML, this diagnosis being confirmed by CSF analyses. Absolute number of CD4+ was 242 cells/μL. An extensive work-up including HIV tests was negative. Ten cases of PML and ICL have previously been reported. Factors contributing to the different outcomes are unknown. Although an effective treatment does not exist for PML, it has been recently demonstrated in vitro that several 5HT2A-receptor antagonists block the JC virus infection. Our patient greatly improved and remains stable 34 months after onset; we describe the potential role of mirtazapine in the treatment of PML.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23465508     DOI: 10.1016/j.jns.2013.02.002

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.

Authors:  Jessie Grewal; Poorvi Dalal; Michelle Bowman; Behiye Kaya; José Javier Otero; Jaime Imitola
Journal:  J Neurovirol       Date:  2016-06-06       Impact factor: 2.643

Review 2.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

Review 3.  Persistence and pathogenesis of the neurotropic polyomavirus JC.

Authors:  Hassen S Wollebo; Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  Ann Neurol       Date:  2015-03-06       Impact factor: 10.422

4.  Dimethyl fumarate associated lymphopenia in clinical practice.

Authors:  Erin E Longbrake; Anne H Cross
Journal:  Mult Scler       Date:  2014-11-28       Impact factor: 6.312

5.  Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia.

Authors:  Asaff Harel; Sam Horng; Tarah Gustafson; Anil Ramineni; Rebecca Straus Farber; Michelle Fabian
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

Review 6.  Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease.

Authors:  Fatima Dhalla; Sarah Murray; Ross Sadler; Benjamin Chaigne-Delalande; Tomohiko Sadaoka; Elizabeth Soilleux; Gulbu Uzel; Joanne Miller; Graham Peter Collins; Christian Simon Ross Hatton; Malini Bhole; Berne Ferry; Helen M Chapel; Jeffrey I Cohen; Smita Y Patel
Journal:  J Clin Immunol       Date:  2014-12-13       Impact factor: 8.317

7.  Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine.

Authors:  Rebekka Kurmann; Christian Weisstanner; Piotr Kardas; Hans H Hirsch; Roland Wiest; Bernhard Lämmle; Hansjakob Furrer; Renaud Du Pasquier; Claudio L Bassetti; Mathias Sturzenegger; Heinz Krestel
Journal:  J Neurovirol       Date:  2015-04-28       Impact factor: 2.643

Review 8.  Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.

Authors:  Christa S Zerbe; Beatriz E Marciano; Rohit K Katial; Carah B Santos; Nick Adamo; Amy P Hsu; Mary E Hanks; Dirk N Darnell; Martha M Quezado; Cathleen Frein; Lisa A Barnhart; Victoria L Anderson; Gulbu Uzel; Alexandra F Freeman; Andrea Lisco; Avindra Nath; Eugene O Major; Elizabeth P Sampaio; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-01-06       Impact factor: 9.079

9.  Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.

Authors:  A H Cross; L Piccio; E E Longbrake; M J Ramsbottom; C Cantoni; L Ghezzi
Journal:  Mult Scler       Date:  2015-10-12       Impact factor: 6.312

10.  Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia.

Authors:  Virginia Sheikh; Brian O Porter; Rebecca DerSimonian; Stephen B Kovacs; William L Thompson; Ainhoa Perez-Diez; Alexandra F Freeman; Gregg Roby; JoAnn Mican; Alice Pau; Adam Rupert; Joseph Adelsberger; Jeanette Higgins; Jeffrey S Bourgeois; Stig M R Jensen; David R Morcock; Peter D Burbelo; Leah Osnos; Irina Maric; Ven Natarajan; Therese Croughs; Michael D Yao; Jacob D Estes; Irini Sereti
Journal:  Blood       Date:  2015-12-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.